In neoadjuvant settings, ctDNA monitoring allows for real-time therapy adjustment. Data from the iSpy platform shows 80% of hormone-positive patients clear ctDNA with half the chemotherapy, enabling de-escalation, while the remaining 20% can be identified for escalated treatment.

A study switching therapy based on ctDNA-detected ESR1 mutations revealed patients felt significantly better after the switch, even without visible tumor progression on scans. This counterintuitive finding suggests molecular progression has a subclinical impact on quality of life, supporting proactive, biomarker-driven treatment changes before patients clinically deteriorate.

Retesting for biomarkers with liquid biopsy in the third-line setting is crucial. It can uncover new, actionable mutations that have emerged during treatment or confirm the absence of resistance mutations, potentially allowing patients to benefit from re-challenging with a previously used targeted therapy.

The landmark DYNAMIC-2 study showed that using ctDNA to guide adjuvant therapy decisions in Stage II colon cancer cut chemotherapy use by 50% (from 30% to 15% of patients). This de-escalation was achieved without any negative impact on patient outcomes, validating the approach.

When GIST progresses on therapy like imatinib, resistance is often heterogeneous. Different metastatic sites within the same patient can develop distinct secondary resistance mutations (e.g., an exon 13 mutation in the liver and an exon 17 in the peritoneum). This complicates subsequent treatment selection and underscores the value of comprehensive testing like ctDNA.

Despite mutation testing being a critical first step for effective treatment planning in gastrointestinal stromal tumors (GIST), a significant number of patients in the United States still do not receive this essential diagnostic. This highlights a major gap between established best practices and real-world clinical application.

The presence of heterogeneous resistance mutations, some of which may be below detection limits, suggests a new strategy. Using a potent, broad-spectrum combination therapy upfront in the second-line setting, rather than sequential monotherapies, could eradicate more resistant clones and give patients a better chance at long-term survival or even a cure.

A study where celecoxib initially failed to show benefit was re-analyzed using ctDNA. The drug provided a substantial survival improvement (HR 0.55-0.58) specifically in ctDNA-positive patients. This demonstrates ctDNA's power not just for prognosis, but as a predictive biomarker to identify which patients will benefit from a targeted therapy.

The standard of care for GIST is evolving to mandate molecular testing at two key points: initial diagnosis and at the time of progression on first-line therapy. Using ctDNA at progression is now deemed critical to identify acquired resistance mechanisms, which directly informs the selection of subsequent, more effective therapies and avoids ineffective treatments.